On September 18, Centrus rose 8.17% in regular trading, trading at $150.22/share, with turnover of $63.78 million. The rally was driven by the announcement of a multi-year agreement to supply Antares with high-assay low-enriched uranium (HALEU).

According to the announcement made on September 17, Centrus signed a definitive multi-year supply deal with Antares, though specific financial terms were not disclosed. This contract marks the latest in a series of HALEU supply agreements Centrus has secured in recent months, following similar deals with Radiant for its Kaleidos microreactors, Oklo for up to five Aurora powerhouses, and X-Energy for its Xe-100 project pipeline. Additionally, the company finalized a contract with the U.S. Department of Energy valued at over $1 billion including all options, aimed at transitioning its HALEU production cascade into commercial operations.

The accumulation of long-term offtake agreements reinforces Centrus's position as a dominant domestic HALEU supplier. The company also recently completed a $500 million equity and warrant offering to fund working capital and corporate purposes, underscoring its capital-intensive expansion trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)